Therapeutics

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Synthetic Lethality and Anti Cancer Drug Discovery

Synthetic Lethality and Anti Cancer Drug Discovery By Jonathan D Moore Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out. Future efforts to drug the… Read More

#Archive

Stem cells
#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biobanking #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The stem cell dilemma: Reprogramming in-house versus off-the-shelf

  by Dr John Comley The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenotypic drug screening assays is now well accepted. Human induced pluripotent stem… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Role Of Immunodeficient Animal Models In Advancing Immuno-Oncology Research

The Role Of Immunodeficient Animal Models In Advancing Immuno-Oncology Research By Dr Michael Seiler From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Biomarkers #Cell therapy #Clinical specialities #Clinical trials #Drug development #Gene therapy #High Content Screening #High throughput screening #Imaging #Immunology #Molecular medicine #Oncology #Precision medicine #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Magnetic Resonance Imaging (MRI) In Drug Development

Magnetic Resonance Imaging (MRI) In Drug Development By Dr Geoff J.M. Parker Magnetic Resonance Imaging (MRI) can be used to provide quantitative measurements in the form of imaging biomarkers. These measurements have a number of attractive characteristics: They are non-invasive, can provide organ and lesion localisation of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Molecular medicine #Orphan drugs #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Drug Discovery in a Multi-Omics World

Drug Discovery in a Multi-Omics World By Mike Furness Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann While Chimeric Antigen Receptor T-cells (CAR-T), have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Using Syngeneic Models for the Discovery of Combination Therapy Targets & Predictive Biomarkers of Immunotherapy Efficacy

By Dr Jean- Pierre Wery Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biomarkers #Business #Cell culture #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Lead discovery #Lead optimisation #Oncology #Regulatory #RNA #Stem cells #Therapeutics

Valuation In Pharma Portfolio Management

Valuation In Pharma Portfolio Management By Dr Michel Azoulay Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Phenotypic Drug Discovery: Striving towards high level biological relevance

Phenotypic Drug Discovery: Striving towards the highest level of biological relevance By Dr John Comley Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target. As such phenotypic… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #In Silico Biology #Lead discovery #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

How Neutron Science Has Enabled Innovation in Drug Design and Delivery

How Neutron Science Has Enabled Innovation in Drug Design and Delivery By Dr Giovanna Fragneto Meeting global health challenges, from cancer to viral infections, requires a profound understanding of living processes – not just at the level of cells but right down at the molecular level. And designing… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Patent Law #PCR #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

The California Institute for Regenerative Medicines Human iPSC Initiative

The California Institute for Regenerative Medicines Human iPSC Initiative By Dr Thomas J. Novak This article discusses large-scale generation of patient-derived induced pluripotent stem cells (iPSCs) to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regenerative Medicine… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #Therapeutics

mRNA Will Revolutionise the Biopharmaceutical Industry

mRNA Will Revolutionise the Biopharmaceutical Industry By Dr Ingmar Hoerr Messenger RNA (mRNA) – the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell’s DNA into the proteins essential for maintaining cell function and ensuring an… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Metabolomics #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Individualised Systems Medicine: Next-Generation Precision Cancer Medicine and Drug Positioning

Individualised Systems Medicine: Next-Generation Precision Cancer Medicine and Drug Positioning By Tea Pemovska, Paaivi Östling, Caroline Heckman, Olli Kallioniemi and Krister Wennerberg A growing number of oncology drugs are currently clinically available and more than a thousand compounds are being developed for oncology indications. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Antimicrobials #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Molecular medicine #Oncology #PCR #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Anti-Infective Immunotherapy For Treating Hospital Acquired Infections

Anti-Infective Immunotherapy For Treating Hospital Acquired Infections By Dr Vu Truong, Dr Nadine Weich, Dr Andreas Loos and Dr Eric Patzer The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order… Read More

#Archive

#Academic #Animal models #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Oncology #Pathology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Experimental therapeutics for celiac disease and refractory celiac disease.

Experimental therapeutics for celiac disease and refractory celiac disease. By Dr Francisco Leon and Beth Llewellyn Celiac disease is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. In celiac patients, gluten causes a systemic autoimmune disease which starts in the small intestine but spreads to… Read More

#Archive